216 related articles for article (PubMed ID: 26313485)
1. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.
Bishop JR; Najjar F; Rubin LH; Guter SJ; Owley T; Mosconi MW; Jacob S; Cook EH
Pharmacogenet Genomics; 2015 Nov; 25(11):548-54. PubMed ID: 26313485
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
Strawn JR; Poweleit EA; Ramsey LB
J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
[No Abstract] [Full Text] [Related]
3. Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism.
Najjar F; Owley T; Mosconi MW; Jacob S; Hur K; Guter SJ; Sweeney JA; Gibbons RD; Cook EH; Bishop JR
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):467-74. PubMed ID: 26262902
[TBL] [Abstract][Full Text] [Related]
4. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.
Chang M; Tybring G; Dahl ML; Lindh JD
Clin Pharmacokinet; 2014 Sep; 53(9):801-11. PubMed ID: 25154506
[TBL] [Abstract][Full Text] [Related]
5. Effects of Cytochrome P450 2C19 Genetic Polymorphisms on Responses to Escitalopram and Levels of Brain-Derived Neurotrophic Factor in Patients With Panic Disorder.
He Q; Mei Y; Liu Y; Yuan Z; Zhang J; Yan H; Shen L; Zhang Y
J Clin Psychopharmacol; 2019; 39(2):117-123. PubMed ID: 30742590
[TBL] [Abstract][Full Text] [Related]
6. Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study.
Strawn JR; Mills JA; Schroeder H; Mossman SA; Varney ST; Ramsey LB; Poweleit EA; Desta Z; Cecil K; DelBello MP
J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32857933
[TBL] [Abstract][Full Text] [Related]
7. Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders.
Aldrich SL; Poweleit EA; Prows CA; Martin LJ; Strawn JR; Ramsey LB
Front Pharmacol; 2019; 10():99. PubMed ID: 30837874
[TBL] [Abstract][Full Text] [Related]
8. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
Huezo-Diaz P; Perroud N; Spencer EP; Smith R; Sim S; Virding S; Uher R; Gunasinghe C; Gray J; Campbell D; Hauser J; Maier W; Marusic A; Rietschel M; Perez J; Giovannini C; Mors O; Mendlewicz J; McGuffin P; Farmer AE; Ingelman-Sundberg M; Craig IW; Aitchison KJ
J Psychopharmacol; 2012 Mar; 26(3):398-407. PubMed ID: 21926427
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study.
Honeycutt DC; Blom TJ; Ramsey LB; Strawn JR; Bruns KM; Welge JA; Patino LR; Singh MK; DelBello MP
J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):42-51. PubMed ID: 38377518
[No Abstract] [Full Text] [Related]
10. Influence of
Islam F; Magarbeh L; Elsheikh SSM; Kloiber S; Espinola CW; Bhat V; Frey BN; Milev R; Soares CN; Parikh SV; Placenza F; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
Can J Psychiatry; 2024 Mar; 69(3):183-195. PubMed ID: 37796764
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.
Jiang T; Rong Z; Xu Y; Chen B; Xie Y; Chen C; Lu Y; Shen Y; Li H; Sun J; Chen H
Clin Drug Investig; 2013 Jan; 33(1):1-9. PubMed ID: 23179471
[TBL] [Abstract][Full Text] [Related]
12. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
Waade RB; Hermann M; Moe HL; Molden E
Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
[TBL] [Abstract][Full Text] [Related]
13. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.
Rudberg I; Mohebi B; Hermann M; Refsum H; Molden E
Clin Pharmacol Ther; 2008 Feb; 83(2):322-7. PubMed ID: 17625515
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.
Rossow KM; Aka IT; Maxwell-Horn AC; Roden DM; Van Driest SL
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 33234666
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic Testing in Patients with Autism Spectrum Disorder Evaluated in a Precision Medicine Clinic.
Goodson R; Wagner J; Sandritter T; Staggs VS; Soden S; Nadler C
J Dev Behav Pediatr; 2023 Oct-Nov 01; 44(8):e505-e510. PubMed ID: 37807195
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram and Sertraline Population Pharmacokinetic Analysis in Pediatric Patients.
Poweleit EA; Taylor ZL; Mizuno T; Vaughn SE; Desta Z; Strawn JR; Ramsey LB
Clin Pharmacokinet; 2023 Nov; 62(11):1621-1637. PubMed ID: 37755681
[TBL] [Abstract][Full Text] [Related]
17. Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder.
He Q; Yuan Z; Liu Y; Zhang J; Yan H; Shen L; Luo X; Zhang Y
Pharmacogenet Genomics; 2017 Aug; 27(8):279-284. PubMed ID: 28614176
[TBL] [Abstract][Full Text] [Related]
18. Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.
Fabbri C; Tansey KE; Perlis RH; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Breen G; Curtis C; Lee SH; Newhouse S; Patel H; O'Donovan M; Lewis G; Jenkins G; Weinshilboum RM; Farmer A; Aitchison KJ; Craig I; McGuffin P; Schruers K; Biernacka JM; Uher R; Lewis CM
Eur Neuropsychopharmacol; 2018 Aug; 28(8):945-954. PubMed ID: 30135031
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
Hicks JK; Bishop JR; Sangkuhl K; Müller DJ; Ji Y; Leckband SG; Leeder JS; Graham RL; Chiulli DL; LLerena A; Skaar TC; Scott SA; Stingl JC; Klein TE; Caudle KE; Gaedigk A;
Clin Pharmacol Ther; 2015 Aug; 98(2):127-34. PubMed ID: 25974703
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
